Host: The Japanese Society of Toxicology
Chemotherapy plays a important role in cancer treatment same as surgery and radiotherapy.
Drug A is evaluated the toxicity profile and the safety in early phase, and evaluated efficacy in late phase with confirmatory clinical study. Although strict trials mention above are performed, there are several unexpected remaining adverse events in clinical practice.
Post-marketing surveillance using ePRO or tracing device information seems important to take measures in unexpected adverse events.
To achieve good clinical practice, it is necessary to collaborate each medical companies without competitive element.
